NeoProteomics

Expertise. Innovation. Results.

Mark R. Chance, Ph.D. - Chief Scientific Officer and Co-Founder

Dr. Mark Chance is a national leader in proteomics research and responsible for determining the scientific vision and direction of NeoProteomics. Dr. Chance is currently Vice Dean for Research, Director of the Center for Proteomics and Bioinformatics, and Professor in the Department of General Medical Sciences at the Case Western Reserve University School of Medicine. He has nationally recognized expertise in quantitative mass spectrometry and 2D-gel analysis technologies that will be crucial to Neo's identification of novel biomarkers. Dr. Chance received his bachelor’s degree in Biology from Wesleyan University and his Ph.D. degree in Biophysics from the University of Pennsylvania in 1986. Dr. Chance furthered his training as a Postdoctoral Research Associate at AT&T Bell Laboratories and then become Assistant Professor in the Department of Chemistry at Georgetown University in 1988. He then moved to Albert Einstein College of Medicine in Bronx, New York and became Professor in the Departments of Physiology & Biophysics and Biochemistry in 1998. He moved to the CWRU School of Medicine in 2005. Dr. Chance’s position as Director of the proteomics center at CWRU has allowed a number of strategic partnerships to develop between NeoProteomics and key faculty working in a number of areas of human disease in the School of Medicine.

Dr. Chance has held a number of appointments of national stature including serving as the Chair of both the NIH Biomedical Technology Center Directors’ Organization from 2001-2003, as well as the Chair of the Scientific Advisory Committee of the Center for Fluorescence Spectroscopy at the University of Maryland in 2005. He has also served on a number of federal advisory panels. He has over 200 professional publications (click on the PubMed link below).

"NeoProteomics' tools, training, and consulting services provide an understanding of drug action at a systems level using efficient algorithms that analyze customer genomics and proteomics data combined with public data and with proprietary company databases. The results are simplified networks describing drug action that identify the key target, biomarkers of its action, and additional up- or downstream targets that mediate response. In addition, Neo has rapid and efficient tools to analyze structures of biologics using mass spectrometry approaches that can define structure and determine equivalency. These tools and services are currently being used by major pharmaceutical companies to develop small molecule drugs and to design novel biologics in cancer and inflammatory diseases." 
                                                                                                                              - Mark R. Chance, Ph.D.

 
Mark R. Chance, Ph.D.
mark.chance@neoproteomics.net
216-870-8873

PubMed Logo